NCT04058067 - To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema | Biotech Hunter

Enrollment

266

Participants

Timeline

Start Date

August 23, 2019

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

Diabetic Macular Edema

Interventions

DRUG

Brolucizumab

5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance

DRUG

Aflibercept

5 x every 4 weeks loading then every 8 weeks maintenance

Trial Locations (24)

100034

Novartis Investigative Site, Beijing

100044

Novartis Investigative Site, Beijing

100191

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

130041

Novartis Investigative Site, Changchun

150001

Novartis Investigative Site, Harbin

200031

Novartis Investigative Site, Shanghai

200080

Novartis Investigative Site, Shanghai

200092

Novartis Investigative Site, Shanghai

210036

Novartis Investigative Site, Nanjing

214002

Novartis Investigative Site, Wuxi

300020

Novartis Investigative Site, Tianjin

300070

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

310009

Novartis Investigative Site, Hangzhou

310014

Novartis Investigative Site, Hangzhou

325027

Novartis Investigative Site, Wenzhou

400038

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

430070

Novartis Investigative Site, Wuhan

510060

Novartis Investigative Site, Guangzhou

515041

Novartis Investigative Site, Shantou

610041

Novartis Investigative Site, Chengdu

2666000

Novartis Investigative Site, Qingdao